FDA Approves Combo Drug Evotaz For Treating HIV-1 Infection in Adults

Bristol-Myers Squibb Co. Jan. 29 announced that the Food and Drug Administration has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for treating HIV-1 infection in adults.

Evotaz is a once-daily pill, combining the protease inhibitor atazanavir, which is marketed as Reyataz capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences Inc., the company said.

The use of Evotaz in patients who have received HIV medication should be guided by their baseline resistance to protease inhibitors, Bristol-Myers said. Evotaz is contraindicated in patients with clinically significant hypersensitivity to any of the ...